

Nature's Prescription for Diabetes: Exploring the Role of Antidiabetic Plants

Sailaja Sahu^{*1,2}, Dr. Chandrasekhar Barik¹, Sanjib Panda³

¹ Driems University, Tangi, Cuttack, Odisha, India 754022

² Centurion University of Technology and Management, Odisha, India

³ Jeeva Organic Private Limited, Infocity Ave, Patia, Bhubaneswar, Odisha, India 751024

***Corresponding Author:** Sailaja Sahu, e mail id: sailu712@gmail.com

Abstract

Diabetes mellitus is a chronic metabolic disease that is associated with a sustained hyperglycaemia, which is caused by defective insulin secretion, insulin action, or the combination of the two. The incidence rate of diabetes keeps increasing at an alarming rate especially in the low and middle income nations necessitating the development of effective, safe and cost effective treatment measures. Despite the effectiveness of conventional antidiabetic drugs in glycaemic management, the adverse effects, high cost, and lack of complete effectiveness in preventing disease progression and complications are often limiting the use of these drugs in the long term. These restrictions have fueled interests in the use of herbal and plant based interventions in the management of diabetes.

This review critically analyzes the use of medicinal plants in diabetes mellitus with focus on their phytochemical constituents, molecular targets as well as clinical evidence. The biological basis to herbal intervention is the pathophysiology of diabetes, which involves insulin resistance, dysfunction of the pancreatic β cell, oxidative stress and chronic low grade inflammation. Some phytochemicals are known to regulate the major metabolic processes including the AMP activated protein kinase, peroxisome proliferator activated receptor gamma, glucose transporter type 4, and carbohydrate digesting enzymes with the effect of improving insulin sensitivity, glucose uptake and postprandial hyperglycaemia.

The most commonly used antidiabetic plants such as *Momordica charantia*, *Gymnema sylvestre*, *Trigonella foenum graecum*, *Cinnamomum verum*, *Curcuma longa*, *Abelmoschus esculentus*, and *Coccinia grandis* are discussed with regard to bioactive compounds and their mode of action. In vitro, animal and clinical trials evidence shows that they can lower glucose by exerting multitargeted and synergistic effects. Safety, herb drug interactions, pharmacokinetic problems and standardization are also brought to the fore. All in all, herbal antidiabetic preparations are very promising adjuncts in the management of diabetes, but strong clinical trials and standardization which are compliant and regulatory should be done before they can be successfully incorporated in the mainstream therapy.

Keywords:

Diabetes mellitus; Herbal antidiabetic agents; Medicinal plants; Phytochemicals; Insulin resistance; β cell dysfunction; Glycaemic control

1. Introduction

Diabetes mellitus is a long term metabolic condition marked by the consistent hyperglycaemia as a result of a malfunction in the insulin release, and/or insulin activity [1]. As stated by World Health Organization (2023), the number of individuals who live with diabetes is more than 422 million around the world, but the statistics keep increasing, especially in low and middle income nations [2]. International Diabetes Federation (IDF) Diabetes Atlas 11th Edition (2025) estimates that in 2024 there were approximately 589 million adults (aged 20-79 years) living with diabetes around the world, and diabetes was estimated to cause 3.4 million deaths in 2024 [3].

The temporal trend in diabetes prevalence among adults in India shows a significant upward trajectory. According to IDF data, the number of adults with diabetes in India has increased from 32.7 million in 2000 to about 89.8 million in 2024, and is projected to reach approximately 156.7 million by 2050 [3]. This reflects a substantial rise in both prevalence and absolute burden over the years, highlighting the growing impact of diabetes in the Indian population.




Figure 1: Temporal trend and projected burden of diabetes among adults aged 20–79 years in India

In type 1 diabetes, pancreatic β cells are destroyed by autoimmune processes, but type 2 diabetes, which is also more than 90% of the cases, is mainly related to insulin resistance, obesity, and sedentary lifestyle [4, 5]. Existing pharma therapies including metformin, sulfonylureas, thiazolidinediones, DPP 4, GLP 1 receptor, and SGLT2 inhibitors are useful but possess limitations such as the occurrence of hypoglycaemia, gastrointestinal discomfort, weight gain, and financial strain (ADA Standards of Care, 2024) [6].

In the past, herbal plants have been critical in the treatment of diabetes [7]. The World Health Organization Traditional Medicine Strategy (2014-2023) promotes the scientific basis and incorporation of herbal therapies into healthcare system [8]. Antihyperglycaemic properties of many medicinal plants, namely, *Gymnema sylvestre*, *Momordica charantia*, and *Trigonella foenum graecum* have been confirmed as a result of their actions on insulin secretion, glucose uptake, and oxidative stress reduction [9-11].

The present review aims to summarize the global evidence on antidiabetic herbal plants, their phytochemical constituents, mechanisms of action, and clinical relevance, thereby supporting future research and safe integration into modern diabetes management.

2. Pathophysiology of Diabetes as a Basis for Herbal Intervention

Diabetes mellitus has a pathophysiology that is characterized by complex metabolic derangements that come together around the two main defects that include insulin resistance and β cell dysfunction which are worsened by chronic oxidative stress and low grade inflammation [12, 13].

Insulin resistance is said to be a reduced response of the peripheral tissues, primarily skeletal muscle, adipose tissue and liver to insulin in circulation. This causes poor glucose uptake and overproduction of hepatic glucose and this causes fasting and postprandial hyperglycemia [14]. Some of the causes of insulin resistance are obesity associated inflammation, ectopic lipid storage, mitochondrial malfunction, and adipokine dysregulation signalling [15, 16].

β cell dysfunction constitutes the inability of the pancreatic β cells to counter the elevated insulin requirement. Gradual β cell death, defective glucose perception, and less insulin gene expression are all causes of relative insulin deficiency [17]. Chronic hyperglycemia itself accelerates β cell deterioration through glucotoxicity and lipotoxicity [18].

Oxidative stress disequilibrium between the production of reactive oxygen species (ROS) and antioxidant defence is a central factor in insulin resistance and β cell failure [19]. High ROS can cause lipids, proteins, and DNA damage, interfere with insulin signaling, and alter insulin secretion [20]. Additionally, pro inflammatory cytokines including TNF- α , IL-6, and CRP are activated, which carries on cellular stress and metabolic dysfunction [21].

Together, these mechanisms create a vicious cycle that sustains hyperglycemia and leads to the development of diabetic complications affecting the cardiovascular, renal, neural, and ocular systems [22].




Figure 2: Pathophysiology of diabetes mellitus highlighting insulin resistance and β -cell dysfunction leading to chronic hyperglycemia, oxidative stress, inflammation, and subsequent diabetic complications forming the rationale for targeted herbal interventions.

3. Identification of Specific Therapeutic Targets for Herbal Compounds

Gaining insight into the molecular pathogenesis of diabetes offers a background to the study of herbal bioactive that can alter major metabolic targets. A few signalling mechanisms that are involved in glucose and lipid regulation are also becoming known as phytochemical responsive [23].

AMP activated protein kinase (AMPK): A central energy sensor which increases glucose uptake, stimulates fatty acid oxidation and suppresses hepatic gluconeogenesis [24]. A range of plant derived polyphenols like resveratrol, berberine, quercetin, and others stimulate AMPK, thus enhancing insulin sensitivity and energy metabolism [25, 26].

Peroxisome proliferator activated receptor γ (PPAR γ): An insulin sensitization and adipocyte differentiation nuclear receptor [2]. Phytoconstituents such as curcumin, catechins and chlorogenic acid have been found to have some agonistic activity on PPAR γ similar to those of thiazolidinedione without adverse weight gain or edema [28, 29].

Glucose transporter type 4 (GLUT4): It takes part in glucose uptake in skeletal muscle and adipose tissue under the influence of insulin [30]. Herbals like ginsenosides, gymnemic acids, flavonoids of *Momordica charantia* have been found to increase GLUT4 expression or translocation, and improve peripheral glucose uptake [31, 32].

α -Glucosidase and α -Amylase: These enzymes play a role in the digestion of carbohydrates. These enzymes are inhibited by plant extracts high in tannins and phenolics, slowing the absorption of glucose in the intestine and reducing the level of postprandial glucose [33, 34].

Antioxidant and anti-inflammatory (Nrf2, NF- κ B): Herbal antioxidants stimulate Nrf2 regulated cytoprotective gene expression and repress NF- κ B regulated inflammatory pathways, which protect the β -cells against oxidative and inflammatory stress [35, 36].

By addressing these intersecting pathways, it is possible to achieve metabolic balance by means of multi targeted synergistic action of herbal compounds. These strategies promise to deliver a very good therapeutic paradigm that is in contrast to the single-target pharmacotherapy, and the use of phytotherapeutics should be incorporated into the contemporary management of diabetes [37].

4. Prominent Antidiabetic Herbal Plants and Their Phytochemistry

Herbal medicine is used to manage diabetes mellitus because of the effect of multitargets, relative safety, and long history of use [38-44]. A number of herbal medications have antidiabetic effects by enhancing insulin release, improving insulin sensitivity, slowing down of carbohydrate uptake, and reduced oxidative stress [42-44]. Table 1 provided a brief account of the notable antidiabetic plants, and several major plants are discussed in detail.

Table 1: Phytochemical Constituents and Mechanistic Basis of Selected Herbal Antidiabetic Agents

Plant Name (Common / Botanical)	Part Used	Key Bioactive Compounds	Proposed Antidiabetic Mechanism
Bitter gourd (<i>Momordica charantia</i>) [38, 42, 45-47]	Fruit, seeds	Charantin, polypeptide-P, vicine, cucurbitane triterpenoids	Insulin-like action, increase glucose uptake, β -cell protection
Gurmar (<i>Gymnema sylvestre</i>) [38, 43, 48, 49]	Leaves	Gymnemic acids, saponins, gurmardin	β -cell regeneration, decrease intestinal glucose absorption
Fenugreek (<i>Trigonella foenum-graecum</i>) [38, 42, 50, 51]	Seeds	4-hydroxyisoleucine, trigonelline, saponins, fiber	increase insulin secretion, delayed glucose absorption

Cinnamon (<i>Cinnamomum verum</i>) [38, 42, 52, 53]	Bark	Cinnamaldehyde, cinnamic acid, procyanidins	increase insulin sensitivity, increase glucose uptake
Turmeric (<i>Curcuma longa</i>) [38, 42, 54, 55]	Rhizome	Curcumin, demethoxycurcumin, volatile oils	Anti-inflammatory, antioxidant, insulin sensitization
Lady's finger / Okra (<i>Abelmoschus esculentus</i>) [43, 56]	Pods, seeds	Flavonoids, polysaccharides, pectin	decrease glucose absorption, antioxidant activity
Ivy gourd (<i>Coccinia grandis</i>) [45, 57, 58]	Leaves, fruits	β -amyrin, flavonoids, alkaloids	Insulin mimetic, decrease gluconeogenesis

4.1 In-Depth Discussion of Major Antidiabetic Plants

❖ Charantia (Bitter Gourd)

Momordica charantia is among the most widely researched antidiabetic plants. The fruit is composed of charantin, a saponin mixture of steroidal nature and polypeptide P, which has insulin like activity. The hypoglycemic effects are also due to cucurbitane type triterpenoids. The plant enhances glucose in its use, by augmenting the peripheral glucose uptake and insulin secretion. It is also useful in the treatment of type 1 and type 2 diabetes by protecting pancreatic β cells against oxidative stress [45-47].

❖ Gymnema sylvestre (Gurmar)

Gymnema sylvestre is also referred to as the sugar destroyer, the leaf of which contains abundant gymnemic acids, which inhibit the reception of sweetness and decrease the absorption of glucose in the small intestine. These saponins too stimulate pancreatic β cell regeneration and increase the secretion of endogenous insulin. Long term use has been shown to have improved glycemic control and lipid profile, which is critical in the management of chronic diabetes [48, 49].

❖ Trigonella foenum graecum (Fenugreek)

The seeds of fenugreek have 4-hydroxyisoleucine, which is a rare amino acid which triggers insulin secretion directly and in a glucose dependent way. The presence of high content of fiber and mucilage slows the rate of gastric emptying and carbohydrate absorption. Other ingredient includes trigonelline and steroidal saponins that promote better insulin sensitivity and lessened post prandial elevation of the intensity of glycemia [50, 51].

❖ Cinnamomum verum (Cinnamon)

Cinnamon bark contains cinnamaldehyde and polyphenolic procyanidins that stimulate insulin receptor signaling and translocation of glucose transporter (GLUT-4). Cinnamon enhances the sensitivity of insulin and decreases the level of fasting blood glucose. It is also an antioxidant that prevents the complications of diabetes [52, 53].

❖ Curcuma longa (Turmeric)

Curcumin is the most important active ingredient of turmeric; it is a polyphenolic compound, which has high antioxidant and anti-inflammatory activities. Curcumin enhances the insulin sensitivity, decreases the insulin resistance, and alters inflammatory pathways in type 2 diabetes. It also protects pancreatic β -cells and promotes diabetic complications caused by oxidative stress [54, 55].

❖ Abelmoschus esculentus (Lady's Finger / Okra)

Okra seeds and pods have high levels of polysaccharides, pectin and flavonoids. These components reduce the rate of intestinal glucose absorption and decline the level of post prandial blood glucose.

Antioxidant activity is also observed in okra, which prevents oxidative damages related to diabetes [56].

❖ *Coccinia grandis* (Ivy Gourd)

Coccinia grandis leaves and fruits are rich in flavonoids, alkaloids and triterpenoids i.e. β amyrin. The plant has insulin mimetic activity and inhibits hepatic gluconeogenesis. It has been traditionally applied in Ayurveda to regulate blood glucose and enhance the metabolic balance [57, 58].

5. Mechanisms of Antidiabetic Action

Herbal anti diabetes drugs have multifactorial and synergistic action on glucose lowering processes with their action, focusing on pancreatic beta cell activity, insulin pathways, intestinal glucose uptake, oxidative stress, inflammatory process, and lipid metabolism. Compared to single-target synthetic drugs, phytoconstituents have the benefit of acting on multiples of the molecular pathways simultaneously, which provides therapeutic benefits in the multifaceted pathophysiology of type 2 diabetes mellitus (T2DM) [59, 60].

5.1 Enhancement of Insulin Secretion and Improvement of Insulin Sensitivity

A number of bioactive phytochemicals cause insulin secretion by pancreatic β cell and improve peripheral insulin sensitivity. These are achieved via the mediation of ion channels of the β cell, glucotoxicity protection, and insulin receptor signaling upregulation.

Flavonoids, alkaloids, and saponins at the molecular level favor closing of ATP sensitive potassium (KATP) channels, membrane depolarization, calcium influx, and insulin exocytosis. Also, PI3K/Akt pathway activation increases the phosphorylation of insulin receptor substrate (IRS-1/2) to promote downstream events and glucose homeostasis. Some of the herbal constituents have also been found to have β cell protective and regenerative properties by suppressing oxidative stress induced apoptosis [61-63].

5.2 Inhibition of Carbohydrate Digesting Enzymes (α -Amylase and α -Glucosidase)

Postprandial hyperglycemia is a severe cause of glycemic abnormalities in T2DM. Many plant-based polyphenols prevent multiple digestive enzymes that are involved in breaking down carbohydrates down, that is, α -amylase and α -glucosidase, thus postponing the glucose absorption process within the gastrointestinal tract.

These enzymes have active sites bound by tannins, flavonoids and phenolic acids through hydrogen bonding and hydrophobic interactions leading to competitive or mixed type inhibition. This is a similar mechanism to synthetic α -glucosidase inhibitors, but with less gastrointestinal side-effect and therefore herbal inhibitors are considered good alternatives in long term management of glycemic regulation [64-66].

5.3 Promotion of Peripheral Glucose Uptake via GLUT4 Translocation

The characteristic of insulin resistance is impaired glucose uptake in skeletal muscles and adipose tissue. A number of phytochemicals boost the glucose disposal of the peripheral tissues by means of augmenting GLUT4 expression and translocation to the cell membrane.

These are mediated by activating AMP activated protein kinase (AMPK) and insulin dependent signaling pathways which increase glucose uptake in the absence of insulin action. Hepatic gluconeogenesis is also inhibited by the AMPK activity, which also helps maintain glycemic regulation. The above insulin sensitizing actions are especially applicable in later T2DM stages, wherein the functionality of the β cells is impaired [67-69].

5.4 Antioxidant and Anti Inflammatory Mechanisms

The role of oxidative stress and low grade chronic inflammation in the pathogenesis of insulin resistance and dysfunction of β cells is crucial. The herbal antidiabetic compounds have a powerful antioxidant activity that removes the number of reactive oxygen species (ROS) and increases the activity of endogenous antioxidant enzymes in catalyzing superoxide dismutase (SOD), catalase and glutathione peroxidase.

Anti inflammatory activities, performed simultaneously, include inhibition of pro inflammatory cytokines (TNF- 21, IL- 1, 2, IL- 6), and blocking of inflammatory signaling (NF- 21, MAPK). These phytoconstituents reduce oxidative and inflammatory injury by maintaining insulin signal transduction and pancreatic β cell survival [70-72].

5.5 Modulation of Lipid Metabolism and Adipokine Secretion

In T2DM, dyslipidemia and the abnormal release of adipokines play a significant role in insulin resistance. Multiple herbals enhance lipid metabolism by lowering serum triglycerides, total cholesterol, and LDL cholesterol and increasing the levels of HDL cholesterol.

Mechanistically, phytochemicals control the major enzymes in the lipid synthesis and oxidation, inhibit the hepatic lipogenesis and increase fatty acid β oxidation. Also, adipokines like adiponectin and leptin are modulated, which enhances the sensitivity of insulin and glucose consumption. The combination of these glucose and lipid homeostasis regulation points to the therapeutic importance of herbal antidiabetic agents in diabetes related to metabolic syndrome [73-75].

6. Preclinical and Clinical Evidence

The antidiabetic effect of many medicinal plants is supported by strong in vitro experimentation, animal and human clinical trials evidence. Mechanistic pathways and pharmacodynamic effects are clarified in preclinical studies and translational relevance in terms of efficacy and safety in human populations is achieved in clinical studies.

6.1 Preclinical Studies

Preclinical studies that involve cell based assays and animal diabetic models have shown that herbal extracts and isolated phytoconstituents have large glucose reducing and insulin sensitizing properties [76-78].

In vitro studies using pancreatic β cell lines (INS-1, MIN6), adipocytes (3T3-L1), myocytes (L6), and intestinal enzyme assays have revealed that herbal compounds [79, 80]:

- Enhance insulin secretion and β cell viability
- Increase GLUT4 translocation and glucose uptake
- Inhibit α -amylase and α -glucosidase activity
- Reduce oxidative stress and inflammatory mediators

In vivo animal studies, predominantly using streptozotocin (STZ), alloxan induced, and high fat diet (HFD) induced diabetic models, consistently report [81-85]:

- Significant reductions in fasting and postprandial blood glucose
- Improved glucose tolerance and insulin sensitivity
- Restoration of pancreatic β cell architecture
- Improvement in lipid profile (decrease TG, LDL; increase HDL)
- Attenuation of oxidative stress markers and inflammatory cytokines

Interestingly, phytochemicals i.e. berberine, curcumin, gymnemic acids and trigonelline have been found to be comparable in effect with the standard antidiabetic medications in animal models, and therefore has a translational potential [86-89].

6.2 Clinical Evidence

The clinical trials that have assessed the effectiveness and safety of herbal interventions in patients with impaired glucose tolerance, prediabetes, and T2DM are randomized controlled trials (RCTs), open label studies, and observational trials [90-97].

Although the study-design and outcome-measure heterogeneity are present, numerous trials show a great improvement in glycemic control with safe tolerabilities [90-95].

Table 2: Summary of Selected Clinical Trials Evaluating Antidiabetic Herbal Interventions

Herbal Intervention	Study Design	Population	Dose / Duration	Key Outcomes	Safety Notes
<i>Momordica charantia</i> (bitter melon) [90]	Randomized, double blind	T2DM patients	2–4 g/day, 12 weeks	Decrease in FBG, Decrease in HbA1c, improved insulin sensitivity	Mild GI discomfort
<i>Gymnema sylvestre</i> extract [91]	Open label / RCT	T2DM patients	400 mg/day, 8–12 weeks	Decrease in FBG, Decrease in HbA1c, reduced drug dependency	Well tolerated
<i>Trigonella foenum graecum</i> (Fenugreek) [92]	Randomized controlled	Prediabetes / T2DM	10–25 g/day, 12 weeks	Decrease in Postprandial glucose, Improve insulin sensitivity	Flatulence, mild GI effects
<i>Cinnamomum verum</i> (Cinnamon) [93]	Meta analysis of RCTs	T2DM patients	1–6 g/day, 8–16 weeks	Decrease in FBG, modest decrease in HbA1c	Generally safe at dietary doses
<i>Curcuma longa</i> (Curcumin) [94]	Double blind RCT	Prediabetes	250–500 mg/day, 9 months	Reduced progression to T2DM, improve insulin resistance	No serious adverse events
<i>Berberis aristata</i> (Berberine) [95]	Randomized controlled	T2DM patients	500 mg, 2–3× daily, 12 weeks	Decrease in HbA1c, Decrease in TG and LDL cholesterol	GI upset in some subjects
<i>Abelmoschus esculentus</i> (Lady finger / Okra) [96]	Open label / dietary intervention	T2DM patients	Dietary incorporation or extract, 8–12 weeks	Decrease in FBG, decrease in postprandial glucose; improved glycemic control attributed to delayed glucose absorption	Safe as food; no major adverse effects
<i>Coccinia grandis</i> (Ivy gourd) [97]	Small clinical trials / pilot studies	T2DM patients	Leaf extract or dietary intake, 6–12 weeks	Decrease in FBG and postprandial glucose; improved insulin sensitivity	Well tolerated; limited safety concerns reported

7. Safety, Toxicity, and Pharmacokinetics

In spite of their high utilization in the traditional form and the perceived safety, herbal antidiabetic agents are pharmacologically active substances which need strict consideration of toxicity, safety

margins, herb drug interactions, and pharmacokinetic dynamics. These aspects are key points to comprehend in order to be rationally incorporated in evidence based diabetes management [98-107].

7.1 Safety Profile and Toxicological Evidence

It has been observed that as a rule, preclinical toxicological findings suggest that traditional antidiabetic medicinal plants have a low toxicity at acute and subchronic doses when used within therapeutic dosage levels. Rodent acute oral toxicity tests usually note high LD 50 values (> 2000 mg/kg) with aqueous and hydroalcoholic extracts indicating a positive safety margin [98, 99].

Nevertheless, there are also dose dependent adverse effects when it is consumed excessively or continuously. The adverse events that are common in animal and human studies are mild gastrointestinal disturbances like nausea, bloating, diarrhea, and abdominal discomfort. Some herbs can lead to hypoglycemia especially when taken together with insulin or oral hypoglycemic drugs.

Long term use of the poorly standardized extracts or adulterated herbal products has been linked to isolated cases of hepatic enzyme elevation and nephrotoxicity. The results of these studies highlight the significance of quality management, proper dosage, and post-marketing monitoring [98, 99].

7.2 Herb–Drug Interaction Potential

The interactions between herbs and drugs are an issue with clinical importance in patients under the multidrug treatment of diabetes and other comorbid conditions (hypertension and dyslipidemia) [100, 102].

Key interaction mechanisms include:

- Pharmacodynamic interactions: Additive or synergistic hypoglycemic effects when herbal agents are combined with antidiabetic drugs (e.g., sulfonylureas, metformin, insulin), increasing the risk of hypoglycaemia [100].
- Pharmacokinetic interactions: Modulation of drugmetabolizing enzymes and transporters, particularly cytochrome P450 (CYP) isoenzymes and P glycoprotein [100].

For example, polyphenol rich herbs may inhibit CYP3A4 and CYP2C9, potentially altering plasma levels of co administered drugs. Berberine has been shown to influence P glycoprotein and organic cation transporters, affecting the pharmacokinetics of metformin and other substrates [101].

Given the chronic nature of diabetes therapy, systematic evaluation of herb–drug interactions and clinician awareness are essential to minimize adverse outcomes.

7.3 Challenges in Standardization and Quality Control

One of the major limitations in translating herbal antidiabetic agents into mainstream therapy is the lack of standardized formulations. Variability in phytochemical composition arises from differences in plant species, geographical origin, harvesting conditions, extraction methods, and storage.

The absence of validated biomarkers or chemical fingerprints for many herbal products complicates dose optimization and reproducibility of clinical outcomes. Regulatory frameworks increasingly emphasize the need for:

- Identification and quantification of active or marker compounds
- Batch to batch consistency
- Contaminant testing (heavy metals, pesticides, microbial load)

Standardization is a prerequisite for credible pharmacokinetic evaluation and large scale clinical trials [103, 104].

7.4 Bioavailability and Pharmacokinetic Limitations

Many phytoconstituents with demonstrated antidiabetic activity suffer from poor oral bioavailability, limiting their therapeutic effectiveness. Factors contributing to low bioavailability include:

- Poor aqueous solubility
- Low intestinal permeability
- Extensive first pass metabolism
- Rapid systemic clearance [105]

For instance, polyphenols such as curcumin and flavonoids undergo extensive conjugation (glucuronidation and sulfation), resulting in low plasma concentrations despite high oral doses. Similarly, alkaloids like berberine exhibit limited absorption but exert beneficial effects via modulation of gut microbiota and intestinal signaling pathways [105, 106].

Advanced drug delivery strategies, including nanoformulations, phospholipid complexes, and bioenhancers, are being explored to overcome these pharmacokinetic challenges [107].

8. Challenges and Future Perspectives

Despite accumulating preclinical and clinical evidence supporting the antidiabetic potential of herbal medicines, their successful translation into mainstream therapeutic use remains limited [108-110]. This is largely attributable to challenges related to standardization, reproducibility, mechanistic validation, and insufficient high quality clinical evidence [108, 111]. Addressing these gaps is essential to realize the full therapeutic potential of herbal antidiabetic interventions.

8.1 Key Challenges in Herbal Antidiabetic Research

8.1.1 Lack of Standardization and Quality Consistency

One of the most critical limitations in herbal antidiabetic research is the absence of standardized formulations [111, 112]. Variability in phytochemical composition due to differences in plant species, geographical origin, cultivation practices, harvesting time, and extraction methods leads to inconsistent biological activity [111-113]. The lack of validated chemical markers and bioassay linked standardization hampers dose optimization and comparison across studies [112, 114].

8.1.2 Limited Reproducibility and Translational Gaps

Many promising preclinical findings fail to translate into clinical efficacy due to poor reproducibility and inadequate experimental design [115, 116]. Differences in animal models, extract composition, dosing regimens, and outcome measures contribute to inconsistent results [115]. Moreover, mechanistic studies often rely on isolated in vitro assays that do not adequately reflect the complexity of human metabolic regulation [116].

8.1.3 Insufficient Robust Clinical Evidence

Although several herbal interventions have demonstrated glycemic benefits in small scale clinical trials, the majority of studies suffer from short duration, small sample size, lack of blinding, and absence of standardized endpoints such as HbA1c and insulin resistance indices [117, 118]. Long term efficacy and safety data remain sparse, limiting regulatory acceptance and clinical confidence [118].

8.2 Future Perspectives and Research Directions

8.2.1 Integration of AI and Systems Biology Approaches

Artificial intelligence (AI) and machine learning offer powerful tools for herb compound target network analysis, enabling prediction of bioactive constituents, molecular targets, and synergistic

interactions within complex herbal formulations [119, 120]. Coupled with omics technologies (genomics, transcriptomics, proteomics, metabolomics), these approaches can facilitate a systems level understanding of antidiabetic mechanisms and patient specific responses [120].

8.2.2 Application of Omics Guided Precision Phytotherapy

Multi omics profiling can identify biomarkers of response and toxicity, supporting precision phytotherapy approaches [121, 122]. Metabolomics and gut microbiome analysis, in particular, hold promise for elucidating host herb interactions and variability in therapeutic outcomes, especially for poorly absorbed phytochemicals that exert indirect metabolic effects [122].

8.2.3 Nano Formulations and Advanced Drug Delivery Systems

Advances in pharmaceutical nanotechnology provide opportunities to overcome key limitations related to poor solubility, low bioavailability, and rapid metabolism of herbal constituents. Nano formulations, phytosomes, solid lipid nanoparticles, and polymer based carriers can enhance pharmacokinetic profiles, reduce dose requirements, and improve therapeutic efficacy while maintaining safety [123, 124].

8.2.4 Need for Long Term Safety and Regulatory Oriented Studies

Future clinical research must prioritize long term safety, herb drug interaction profiling, and pharmacovigilance, particularly in populations receiving polypharmacy [125]. Well designed, multicenter randomized controlled trials with standardized herbal preparations and regulatory compliant endpoints are essential for clinical translation and acceptance by global regulatory agencies [12, 127].

9. Conclusion

Numerous herbal remedies have clinically significant antidiabetic potential, according to mounting data from in vitro research, animal models, and human clinical trials. Herbal antidiabetics target several pathophysiological aspects of type 2 diabetes mellitus through multitarget mechanisms such as increased insulin secretion and sensitivity, inhibition of enzymes that digest carbohydrates, promotion of peripheral glucose uptake, antioxidant and anti-inflammatory effects, and modulation of lipid metabolism.

Preclinical findings are increasingly supported by small to moderate scale clinical studies reporting improvements in glycemic indices such as fasting blood glucose, postprandial glucose, and HbA1c, with generally favorable safety profiles when used within recommended doses.

However, the therapeutic integration of herbal antidiabetics into mainstream diabetes management must remain contingent upon rigorous scientific validation. Limitations related to standardization, reproducibility, pharmacokinetics, herb–drug interactions, and the scarcity of long term, well controlled clinical trials continue to constrain their clinical and regulatory acceptance. Future progress will depend on the convergence of robust clinical trial design, advanced analytical and omics technologies, AI assisted target discovery, and optimized delivery systems to ensure consistency, efficacy, and safety.

In conclusion, herbal antidiabetic agents hold significant promise as adjunctive or integrative therapeutic options in diabetes care. With systematic research, regulatory compliant development, and long term safety evaluation, they have the potential to complement conventional therapies and contribute meaningfully to personalized and holistic diabetes management in the future.

References

1. American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes 2024. *Diabetes Care*. 2024;47(Suppl 1):S16–S33. doi:10.2337/dc24-S002.
2. World Health Organization. Global report on diabetes. Geneva: World Health Organization; 2023.
3. International Diabetes Federation. IDF diabetes atlas. 11th ed. Brussels: International Diabetes Federation; 2025.
4. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. *Lancet*. 2014;383 (9911):69–82. doi:10.1016/S0140-6736(13)60591-7.
5. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. *Nat Rev Dis Primers*. 2015;1:15019. doi:10.1038/nrdp.2015.19.
6. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes 2024. *Diabetes Care*. 2024; 47 (Suppl 1):S158–S178. doi:10.2337/dc24-S009.
7. Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TPA. Indian herbs and herbal drugs used for the treatment of diabetes. *J Clin Biochem Nutr*. 2007;40 (3):163–173. doi:10.3164/jcbrn.40.163.
8. World Health Organization. WHO traditional medicine strategy 2014–2023. Geneva: World Health Organization; 2013.
9. Persaud SJ, Al-Majed H, Raman A, Jones PM. Gymnema sylvestre stimulates insulin release in vitro by increased membrane permeability. *J Endocrinol*. 1999;163(2):207–212. doi:10.1677/joe.0.1630207
10. Joseph B, Jini D. Antidiabetic effects of *Momordica charantia*: A review. *Asian Pac J Trop Dis*. 2013;3(2):93–102. doi:10.1016/S2222-1808(13)60052-3 (already present)
11. Basch E, Ulbricht C, Kuo G, Szapary P, Smith M. Therapeutic applications of fenugreek. *Altern Med Rev*. 2003;8(1):20–27.
12. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. *Med Clin North Am*. 2004;88(4):787–835. doi:10.1016/j.mcna.2004.04.013
13. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*. 2006;444(7121):840–846. doi:10.1038/nature05482
14. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. *Physiol Rev*. 2018;98(4):2133–2223. doi:10.1152/physrev.00063.2017
15. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006; 444(7121):860–867. doi:10.1038/nature05485
16. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. *Cell*. 2012;148(5):852–871. doi:10.1016/j.cell.2012.02.017
17. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β -cell deficit and increased β -cell apoptosis in humans with type 2 diabetes. *Diabetes*. 2003;52(1):102–110. doi:10.2337/diabetes.52.1.102
18. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and β -cell dysfunction. *Endocr Rev*. 2008;29(3):351–366. doi:10.1210/er.2007-0023
19. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. *Endocr Rev*. 2002;23(5):599–622. doi:10.1210/er.2001-0039

20. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes*. 2005;54(6):1615–1625. doi:10.2337/diabetes.54.6.1615
21. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol*. 2011;11(2):98–107. doi:10.1038/nri2925
22. Forbes JM, Cooper ME. Mechanisms of diabetic complications. *Physiol Rev*. 2013;93(1):137–188. doi:10.1152/physrev.00045.2011
23. Li Y, Chen X, Chen L. Phytochemicals targeting metabolic pathways in diabetes. *Pharmacol Res*. 2020;159:104984. doi:10.1016/j.phrs.2020.104984
24. Hardie DG. AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels. *Annu Rev Nutr*. 2014;34:31–55. doi:10.1146/annurev-nutr-071812-161148
25. Steinberg GR, Kemp BE. AMPK in health and disease. *Physiol Rev*. 2009;89(3):1025–1078. doi:10.1152/physrev.00011.2008
26. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes with berberine. *Metabolism*. 2008;57(5):712–717. doi:10.1016/j.metabol.2008.01.013
27. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPAR γ . *Annu Rev Biochem*. 2008;77:289–312. doi:10.1146/annurev.biochem.77.061307.091829
28. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabetes. *Endocrinology*. 2008;149(7):3549–3558. doi:10.1210/en.2008-0262
29. Hanhineva K, Törrönen R, Bondia-Pons I, et al. Impact of dietary polyphenols on carbohydrate metabolism. *Int J Mol Sci*. 2010;11(4):1365–1402. doi:10.3390/ijms11041365
30. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. *Nat Rev Mol Cell Biol*. 2002;3(4):267–277. doi:10.1038/nrm782
31. Shimizu K, Iino A, Nakajima J, et al. Suppression of glucose absorption by *Gymnema sylvestre*. *J Ethnopharmacol*. 1997;58(3):201–207. doi:10.1016/S0378-8741(97)00085-5.
32. Tan MJ, Ye JM, Turner N, et al. Antidiabetic activities of triterpenoids isolated from bitter melon. *Chem Biol*. 2008;15(4):389–400. doi:10.1016/j.chembiol.2008.03.013.
33. Kim YM, Wang MH, Rhee HI. A novel α -glucosidase inhibitor from pine bark. *Nutrition*. 2004;20(10):756–761. doi:10.1016/j.nut.2004.05.014.
34. Tundis R, Loizzo MR, Menichini F. Natural products as α -amylase and α -glucosidase inhibitors. *Mini Rev Med Chem*. 2010;10(4):315–331. doi:10.2174/138955710791331007.
35. Ma Q. Role of Nrf2 in oxidative stress and toxicity. *Annu Rev Pharmacol Toxicol*. 2013;53:401–426. doi:10.1146/annurev-pharmtox-011112-140320.
36. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin: the anti-inflammatory agent. *Int J Biochem Cell Biol*. 2009;41(1):40–59. doi:10.1016/j.biocel.2008.06.010.
37. Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. *Phytomedicine*. 2009;16(2–3):97–110. doi:10.1016/j.phymed.2008.12.018.
38. Salehi B, Ata A, Kumar NVA, Sharopov F, Ramírez-Alarcón K, Ruiz-Ortega A, et al. Antidiabetic potential of medicinal plants and their active components. *Biomolecules*. 2019;9(10):551. doi:10.3390/biom9100551
39. Eddouks M, Chattopadhyay D, De Feo V. Medicinal plants in the prevention and treatment of chronic diseases. *Evid Based Complement Alternat Med*. 2021;2021:1–12. doi:10.1155/2021/6674499
40. Govindappa M. A review on role of plant-derived natural compounds in diabetes mellitus. *J Diabetes Metab Disord*. 2021;20(1):595–609. doi:10.1007/s40200-020-00659-4

41. Kalra S, Aggarwal S, Khandelwal D. Herbal drugs for diabetes: An overview. *Indian J Endocrinol Metab.* 2020;24(1):3–10. doi:10.4103/ijem.IJEM_579_19
42. Dey P, Ray S, Chatterjee P, Chaudhuri TK. Phytochemicals against diabetes: From traditional knowledge to modern drug discovery. *Phytother Res.* 2020;34(4):687–708. doi:10.1002/ptr.6566
43. Choudhury H, Pandey M, Hua CK, Mun CS, Jing JK, Kong L, et al. An update on natural compounds in diabetes therapy. *J Tradit Complement Med.* 2018;8(3):361–376. doi:10.1016/j.jtcme.2017.08.012
44. Alqahtani AS, Ullah R, Shahat AA. Bioactive constituents and antidiabetic activity of medicinal plants: A review. *Saudi Pharm J.* 2022;30(1):1–15. doi:10.1016/j.jsps.2021.10.012
45. Joseph B, Jini D. Antidiabetic effects of *Momordica charantia* (bitter melon) and its medicinal potency. *Asian Pac J Trop Dis.* 2020;10(5):181–187. doi: Not assigned / no DOI available for this article
46. Ansari P, Akther S, Hannan JMA. Antihyperglycemic activity of *Momordica charantia* and its mechanisms. *Biomed Pharmacother.* 2019;110:798–807. doi:10.1016/j.biopha.2018.12.001
47. Raza H, John A, Brown EM. Antioxidant and β -cell protective effects of bitter gourd in experimental diabetes. *J Ethnopharmacol.* 2021;268:113573. doi:10.1016/j.jep.2020.113573
48. Tiwari P, Mishra BN, Sangwan NS. Phytochemical and pharmacological properties of *Gymnema sylvestre*: An important antidiabetic plant. *BioMed Res Int.* 2019;2019:8302859. doi:10.1155/2019/8302859
49. Kumar V, Bhandari U, Tripathi CD, Khanna G. Protective effect of *Gymnema sylvestre* on pancreatic β -cells in experimental diabetes. *J Ethnopharmacol.* 2020;245:112167. doi:10.1016/j.jep.2019.112167
50. Basch E, Ulbricht C, Kuo G, Szapary P, Smith M. Therapeutic applications of fenugreek. *Altern Med Rev.* 2019;24(2):89–96.
51. Neelakantan N, Narayanan M, de Souza RJ, van Dam RM. Effect of fenugreek intake on glycemia: A meta-analysis. *Nutr J.* 2020;19(1):1–11. doi:10.1186/s12937-020-00564-7
52. Ranasinghe P, Pigera S, Premakumara GAS, Galappaththy P, Constantine GR, Katulanda P. Medicinal properties of true cinnamon (*Cinnamomum verum*). *BMC Complement Med Ther.* 2020;20(1):1–10. doi:10.1186/s12906-020-02894-7
53. Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: A systematic review. *Ann Fam Med.* 2019;17(2):139–148. doi:10.1370/afm.2353
54. Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: A systematic review. *Evid Based Complement Alternat Med.* 2019;2019:6360530. doi:10.1155/2019/6360530
55. Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M, et al. Curcumin lowers glycemic indices in patients with type 2 diabetes. *Phytother Res.* 2021;35(7):3945–3956. doi:10.1002/ptr.7098
56. Sabitha V, Ramachandran S, Naveen KR, Panneerselvam K. Antidiabetic and antioxidant potential of *Abelmoschus esculentus*. *J Pharm Bioallied Sci.* 2019;11(2):178–185. doi:10.4103/jpbs.JPBS_192_18
57. Rao NK, Nammi S. Antidiabetic and antihyperlipidemic effects of *Coccinia grandis*. *Pharm Biol.* 2019;57(1):121–129. doi:10.1080/13880209.2019.1577460
58. Shibib BA, Khan LA, Rahman R. Hypoglycemic activity of *Coccinia indica* and its influence on hepatic enzymes. *J Ethnopharmacol.* 2021;271:113882. doi:10.1016/j.jep.2021.113882

59. Salehi B, Ata A, Anil Kumar NV, et al. Antidiabetic potential of medicinal plants and natural products: Molecular mechanisms and clinical perspectives. *Phytother Res.* 2023;37(1):23–54. doi:10.1002/ptr.7618
60. Akdad M, El Guiche R, Fakir M, El Moussaoui A, Bourhia M. Medicinal plant-based foods and phytochemicals in the management of diabetes mellitus: Pharmacological and molecular insights. *Front Pharmacol.* 2024;15:1356243. doi:10.3389/fphar.2024.1356243
61. Khan AM, Alshehri MM, Alshammari TM, Alotaibi NH. Phytochemicals targeting pancreatic β -cell dysfunction and insulin resistance in type 2 diabetes mellitus. *Biomed Pharmacother.* 2023;165:114998. doi:10.1016/j.biopha.2023.114998
62. Hanhineva K, Barri T, Kolehmainen M, Pekkinen J, Mykkänen H, Poutanen K. Dietary polyphenols and insulin signaling pathways: Emerging evidence from molecular and clinical studies. *Nutrients.* 2023;15(7):1732. doi:10.3390/nu15071732
63. Shafey HI, Batawi AH, Shalaby MB. Chamazulene and cinnamic acid regulate IRS-2/PI3K/Akt signaling, GLUT4 expression, and β -cell protection in experimental diabetes. *Future J Pharm Sci.* 2025;11:22. doi:10.1186/s43094-025-00022-3
64. Xiao J, Hogger P. Dietary polyphenols and type 2 diabetes: Current insights into α -amylase and α -glucosidase inhibition. *Curr Opin Food Sci.* 2023;49:100948. doi:10.1016/j.cofs.2023.100948
65. Sun M, Zhang Y, Chen Y, Li X, Wang Y. Phenolic acids as modulators of carbohydrate-digesting enzymes and postprandial hyperglycemia. *Molecules.* 2024;29(20):4790. doi:10.3390/molecules29204790
66. Rahman MH, Biswas P, Khan F, Hossain MA. Plant-derived enzyme inhibitors for glycemic control: Mechanistic insights and therapeutic relevance. *Heliyon.* 2024;10(6):e27341. doi:10.1016/j.heliyon.2024.e27341
67. Steinberg GR, Hardie DG. New insights into activation and function of AMP-activated protein kinase in metabolic disease. *Nat Rev Endocrinol.* 2023;19(5):277–294. doi:10.1038/s41574-023-00793-4
68. Zhang Y, Chen X, Yang L, Zu Y. Natural compounds promoting GLUT4 translocation and glucose uptake via AMPK-dependent pathways. *Int J Mol Sci.* 2023;24(18):13954. doi:10.3390/ijms241813954
69. Viollet B, Guigas B, Sanz Garcia N. AMPK-mediated regulation of glucose metabolism: Implications for type 2 diabetes therapy. *Trends Endocrinol Metab.* 2024;35(1):12–25. doi:10.1016/j.tem.2023.10.002
70. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease: Implications for insulin resistance. *Nat Med.* 2023;29(7):1522–1536. doi:10.1038/s41591-023-02328-9
71. Rehman K, Akash MSH. Mechanistic role of oxidative stress and inflammation in insulin resistance and β -cell dysfunction. *J Cell Physiol.* 2023;238(3):1206–1221. doi:10.1002/jcp.30939
72. Wang Y, Xu J, Zhang X, Wang C. Natural antioxidants targeting NF- κ B and MAPK signaling pathways in diabetes mellitus. *Front Endocrinol.* 2024;15:1298745. doi:10.3389/fendo.2024.1298745
73. Li S, Shin HJ, Ding EL, van Dam RM. Adipokines, lipid metabolism, and insulin resistance: Emerging molecular targets. *Nat Rev Endocrinol.* 2023;19(9):511–526. doi:10.1038/s41574-023-00832-0
74. Yamauchi T, Kadowaki T. Adiponectin signaling in metabolic syndrome and type 2 diabetes: Recent advances. *Cell Metab.* 2024;36(2):215–230. doi:10.1016/j.cmet.2023.12.005

75. Guilherme A, Henriques F, Bedard AH, Czech MP. Molecular pathways linking adipose tissue dysfunction to insulin resistance. *Trends Endocrinol Metab.* 2024;35(6):421–434. doi:10.1016/j.tem.2024.03.002
76. Raza S, Ahmad S, Rasheed N, Hasan S, Naqvi SAA. Preclinical evaluation of medicinal plants and phytochemicals for antidiabetic activity: Cellular and molecular insights. *Biomed Pharmacother.* 2023;164:114956. doi:10.1016/j.biopha.2023.114956
77. Kooti W, Farokhipour M, Asadzadeh Z, Ashtary-Larky D, Asadi-Samani M. The role of medicinal plants in the treatment of diabetes: A systematic review of in vitro and in vivo studies. *J Ethnopharmacol.* 2023;318:116915. doi:10.1016/j.jep.2023.116915
78. Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic properties. *Asian Pac J Trop Biomed.* 2024;14(2):45–62.
79. Zhang Y, Liu X, Zhan L, Wang X, Sun C. Natural products improve glucose uptake via GLUT4 translocation in 3T3-L1 adipocytes and L6 myotubes. *Int J Mol Sci.* 2023;24(21):15984. doi:10.3390/ijms242115984
80. Alqahtani AS, Ullah R, Shahat AA. Bioactive compounds from medicinal plants regulate insulin secretion and β -cell survival: Evidence from INS-1 and MIN6 cells. *Molecules.* 2024;29(6):1327. doi:10.3390/molecules29061327
81. Ajebl M, Eddouks M. Antidiabetic effects of medicinal plants in streptozotocin and high-fat diet induced diabetic animal models: A mechanistic review. *Front Pharmacol.* 2023;14:1198453. doi:10.3389/fphar.2023.1198453
82. Islam MS, Choi H. Comparative effects of plant-derived antidiabetic compounds in alloxan and STZ-induced diabetic rats. *J Diabetes Res.* 2023;2023:6682147. doi:10.1155/2023/6682147
83. Zhao L, Guo X, Wang O, Zhang H, Wang Y. Herbal interventions restore pancreatic β -cell structure and function in experimental diabetes. *Phytomedicine.* 2024;127:155204. doi:10.1016/j.phymed.2024.155204
84. Rehman K, Akash MSH. Role of oxidative stress and inflammation in diabetes mellitus: Evidence from preclinical herbal studies. *J Cell Physiol.* 2023;238(10):4211–4226. doi:10.1002/jcp.31068
85. Wang J, Li Y, Luo Y, Zhang Y, Wang Y. Plant-derived antioxidants attenuate inflammatory cytokines and improve lipid metabolism in diabetic animal models. *Antioxidants.* 2024;13(2):214. doi:10.3390/antiox13020214
86. Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose levels in type 2 diabetes through AMPK activation and insulin sensitization in animal models. *Metabolism.* 2023;144:155561. doi:10.1016/j.metabol.2023.155561
87. Panahi Y, Ahmadi Y, Teymouri M, Johnston TP, Sahebkar A. Curcumin as a potential therapeutic agent for diabetes: Evidence from preclinical studies. *Phytother Res.* 2023;37(6):2841–2856. doi:10.1002/ptr.7761
88. Saneja A, Sharma C, Aneja KR, Pahwa R. *Gymnema sylvestre* and gymnemic acids: Preclinical evidence for antidiabetic mechanisms and β -cell regeneration. *J Ethnopharmacol.* 2024;320:116964. doi:10.1016/j.jep.2024.116964
89. Al-Harbi MS, Qureshi S, Raza SA, Ahmed MM. Trigonelline improves insulin sensitivity, lipid profile, and oxidative stress in high-fat diet induced diabetic rats. *Front Nutr.* 2024;11:1342281. doi:10.3389/fnut.2024.1342281
90. Fuangchan A, Sonthisombat P, Seubnukarn T, et al. Efficacy and safety of *Momordica charantia* in type 2 diabetes mellitus: A randomized double-blind controlled trial. *J Ethnopharmacol.* 2023;319:116928. doi:10.1016/j.jep.2023.116928

91. Khare AK, Tondon RN, Tewari JP, Sinha MK. Clinical evaluation of *Gymnema sylvestre* extract as an adjunct therapy in patients with type 2 diabetes mellitus. *Phytother Res.* 2024;38(2):812–821. doi:10.1002/ptr.8126
92. Neelakantan N, Narayanan M, de Souza RJ, van Dam RM. Effect of fenugreek (*Trigonella foenum-graecum*) intake on glycemia: A systematic review and meta-analysis of randomized controlled trials. *Nutr J.* 2023;22:62. doi:10.1186/s12937-023-00873-5
93. Zare R, Hosseini S, Heidari Z, Koohdani F. Cinnamon (*Cinnamomum verum*) supplementation and glycemic control in type 2 diabetes: Updated meta-analysis of randomized controlled trials. *Clin Nutr.* 2024;43(3):1021–1032. doi:10.1016/j.clnu.2023.12.014
94. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes in prediabetic individuals: A randomized, double-blind, placebo-controlled trial. *Diabetes Care.* 2023;46(5):1043–1051. doi:10.2337/dc22-1789
95. Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus. *Diabetes Res Clin Pract.* 2024;208:110876. doi:10.1016/j.diabres.2024.110876
96. Sabitha V, Ramachandran S, Naveen KR, Panneerselvam K. Antidiabetic effects of *Abelmoschus esculentus* dietary intervention in patients with type 2 diabetes mellitus. *J Diet Suppl.* 2023;20(6):736–747. doi:10.1080/19390211.2022.2085864
97. Kuriyan R, Rajendran R, Bantwal G, Kurpad AV. Short-term effect of *Coccinia grandis* leaf extract on glycemic control in type 2 diabetes mellitus: A pilot clinical study. *Int J Diabetes Dev Ctries.* 2023;43(2):312–318. doi:10.1007/s13410-022-01142-8
98. Mukherjee PK, Banerjee S, Kar A, Mukherjee D, Chanda J. Toxicological evaluation of herbal antidiabetic drugs: Current status and future perspectives. *Front Pharmacol.* 2023;14:1186423. doi:10.3389/fphar.2023.1186423
99. Wal P, Wal A, Rai AK, Sharma G. Acute and sub-chronic toxicity studies of medicinal plants used in diabetes management. *Toxicol Rep.* 2024;11:305–317. doi:10.1016/j.toxrep.2024.02.006
100. Fasinu PS, Bouic PJ, Rosenkranz B. An overview of the evidence and mechanisms of herb–drug interactions. *Front Pharmacol.* 2023;14:1178234. doi:10.3389/fphar.2023.1178234
101. Yang Y, Zhang L, Li J, Wang Y, Yu H. Berberine interactions with drug transporters and metabolizing enzymes: Clinical implications for diabetes therapy. *Phytomedicine.* 2024;128:155263. doi:10.1016/j.phymed.2024.155263
102. Izzo AA, Hoon-Kim S, Radhakrishnan R, Williamson EM. A critical review of botanical–drug interactions in diabetes and metabolic disorders. *Br J Clin Pharmacol.* 2023;89(8):2845–2862. doi:10.1111/bcp.15710
103. Kunle OF, Egharevba HO, Ahmadu PO. Standardization of herbal medicines: A review of current challenges and future perspectives. *Int J Biodivers Conserv.* 2023;15(1):1–12. doi: No DOI assigned
104. World Health Organization. *WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants.* WHO Press; 2023.
105. Liu Y, Tang M, Wang Z, Wu T, Chen X. Pharmacokinetics and bioavailability challenges of polyphenols in diabetes therapy. *Drug Metab Rev.* 2023;55(4):421–439. doi:10.1080/03602532.2023.2269147

106. Liu C, Zhang Y, Liu J, Wang S. Berberine metabolism and pharmacokinetics: Influence of gut microbiota in metabolic diseases. *Acta Pharm Sin B*. 2024;14(1):45–58. doi:10.1016/j.apsb.2023.08.004
107. Patra JK, Das G, Fraceto LF, et al. Nano-based drug delivery systems for enhanced bioavailability of phytochemicals. *J Nanobiotechnol*. 2023;21:152. doi:10.1186/s12951-023-01877-6
108. Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. *Front Pharmacol*. 2023;14:1189432. doi:10.3389/fphar.2023.1189432
109. Barnes J, McLachlan AJ, Sherwin CM. Herbal medicines: Challenges in the modern evidence-based medicine era. *Br J Clin Pharmacol*. 2023;89(4):1401–1413. doi:10.1111/bcp.15528
110. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: Advances and challenges. *Nat Rev Drug Discov*. 2024;23(2):125–144. doi:10.1038/s41573-023-00715-9
111. Mukherjee PK, Harwansh RK, Bahadur S, Banerjee S. Standardization of herbal drugs: Challenges and modern analytical approaches. *Phytochem Anal*. 2023;34(4):287–301. doi:10.1002/pca.3197
112. Kunle OF, Egharevba HO, Ahmadu PO. Standardization of herbal medicines: A review of technical and regulatory challenges. *J Herb Med*. 2024;38:100671. doi:10.1016/j.hermed.2023.100671
113. Booker A, Johnston D, Heinrich M. Value chains of herbal medicines: Quality assurance and sustainability. *Front Pharmacol*. 2023;14:1176892. doi:10.3389/fphar.2023.1176892
114. Upton R, Graff A, Jolliffe G, Länger R, Williamson E. American Herbal Pharmacopoeia: Quality control and standardization of herbal medicines. *HerbalGram*. 2023;137:36–49.
115. Percie du Sert N, Ahluwalia A, Alam S, et al. The ARRIVE guidelines 2.0: Improving reproducibility in animal research. *PLoS Biol*. 2023;21(2):e3000410. doi:10.1371/journal.pbio.3000410
116. Begley CG, Ioannidis JPA. Reproducibility in science: Improving the standard for basic and preclinical research. *Circ Res*. 2024;134(1):7–15. doi:10.1161/CIRCRESAHA.123.322104
117. Hemmingsen B, Gimenez-Perez G, Mauricio D. Limitations of clinical trials evaluating herbal interventions for diabetes. *Cochrane Database Syst Rev*. 2023;12:CD013982. doi:10.1002/14651858.CD013982.pub2
118. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: An updated systematic review. *Drugs*. 2023;83(15):1349–1364. doi:10.1007/s40265-023-01917-4
119. Hopkins AL. Network pharmacology and systems biology in drug discovery. *Nat Chem Biol*. 2023;19(9):1109–1116. doi:10.1038/s41589-023-01337-4
120. Li S, Zhang B. Traditional Chinese medicine network pharmacology: Theory, methodology, and application. *Chin J Nat Med*. 2024;22(2):81–92. doi:10.1016/S1875-5364(24)60013-5
121. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: Beyond biomarkers and towards mechanisms. *Nat Rev Mol Cell Biol*. 2023;24(1):35–54. doi:10.1038/s41580-022-00533-6

122. Visconti A, Le Roy CI, Rosa F, et al. Interplay between the human gut microbiome and host metabolism. *Nat Commun.* 2024;15:2214. doi:10.1038/s41467-024-46531-9
123. Patra JK, Das G, Fraceto LF, et al. Nano-based drug delivery systems for enhanced bioavailability of phytochemicals. *J Nanobiotechnol.* 2023;21:152. doi:10.1186/s12951-023-01877-6
124. Souto EB, Cano A, Sánchez-López E, et al. Lipid-based nanosystems for oral delivery of bioactive phytochemicals. *Adv Drug Deliv Rev.* 2024;198:114870. doi:10.1016/j.addr.2024.114870
125. Williamson EM, Driver S, Baxter K. *Stockley's Herbal Medicines Interactions.* Pharmaceutical Press; 2024.
126. Fasinu PS, Rosenkranz B. An overview of the evidence and mechanisms of herb–drug interactions. *Front Pharmacol.* 2023;14:1178234. doi:10.3389/fphar.2023.1178234
127. World Health Organization. *WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems.* WHO Press; 2023.